代谢相关脂肪性肝病与慢性肾脏病的研究进展  

Research progress of Metabolic dysfunction associated fatty liver disease and chronic kidney disease

作　　者：王瑾 张耀武 WANG Jin;ZHANG Yao-wu(.Fenyang College of Shanxi Medical University,Fenyang Shanxi,032200,China.)

机构地区：[1]山西医科大学汾阳学院,山西汾阳032200 [2]山西省汾阳医院感染性疾病科

出　　处：《中西医结合肝病杂志》2025年第3期389-392,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：2020年,国际医学专家提出将非酒精性脂肪性肝病(NAFLD)更名为代谢相关脂肪性肝病(MAFLD),该命名变化需要对其与慢性肾脏疾病(CKD)的风险关系进行重新评估。目前为止,大量研究表明MAFLD与CKD密切相关,本文总结了MAFLD与CKD之间的潜在病理生理机制,以及可能对这两种疾病都有益的潜在药物治疗。In 2020,the term metabolic dysfunction associated fatty liver disease(MAFLD)was proposed to replace the old term non-alcoholic fatty liver disease(NAFLD).This definition change has led to a reassessment of its association with the risk of chronic kidney disease(CKD).To date,a large number of studies have observed a close relationship between MAFLD and CKD,and this article summarizes the potential pathophysiological mechanisms between MAFLD and CKD,as well as potential drug treatments that may be beneficial for both diseases.

关 键 词：代谢相关脂肪性肝病 慢性肾脏疾病 病理生理机制 内科治疗 

分 类 号：R575.5[医药卫生—消化系统]